Eikon Therapeutics filed for a U.S. IPO, a test of whether recent market optimism can sustain new biotech listings, BioCentury reported. Separately, Aktis received a warm reception in public markets, which analysts say could open the door for follow‑on offerings and new IPOs. Together the filings and positive aftermarket interest indicate renewed investor appetite, though bankers will watch pricing and early trading to gauge sustainability.